Apolipoprotein B/Apolipoprotein A1 ratio is an independent prognostic factor in pancreatic cancer

Transl Oncol. 2024 Nov 25:51:102208. doi: 10.1016/j.tranon.2024.102208. Online ahead of print.

Abstract

Objective: The relationship between serum lipids and prognosis of pancreatic cancer has not been confirmed. Our purpose in the study was to investigate the associations between serum lipids level and prognosis in patients with pancreatic cancer.

Methods: A retrospective study was performed on 286 pancreatic cancer patients who admitted to our hospital from January 1, 2017 to December 31, 2021. Serum lipids level were recorded. Clinical-pathological characteristics, oncologic outcomes, progression free survival (PFS) and overall survival (OS) were collected. The prognostic significance was determined by Kaplan-Meier analysis and Cox proportional hazards regression model.

Results: Regarding serum lipids level, compared to normal apolipoprotein B/ apolipoprotein A (ApoB/ApoA1), high ApoB/ApoA1 level indicated a shorter OS (HR:2.028, 95% CI: 1.174-2.504, P = 0.011) and a shorter PFS (HR:1.800, 95% CI: 1.076-3.009, P = 0.025). Other serum lipid molecules were not associated with PFS and OS.

Conclusion: ApoB/ApoA1 might be an independent prognostic factor of pancreatic cancer.

Keywords: ApoB/ApoA1 ratio; Marker; Pancreatic cancer; Prognosis; overall survival.